{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:52:21Z","timestamp":1775710341116,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>This retrospective study evaluated real-world outcomes of standalone iDose TR intracameral travoprost implant administration. Sixty-five consecutive standalone iDose TR implantations performed by a single surgeon were analyzed. Patients were pseudophakic, had a diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT), and had a history of a prior non-filtering glaucoma procedure (e.g., selective laser trabeculoplasty [SLT] or bimatoprost intracameral implant) performed beyond the preceding 6 months. Intraocular pressure (IOP) and medications were measured for 12 months postoperatively. Subgroup analysis was stratified by history of SLT treatment and glaucoma severity. If target IOP was not attained, secondary minimally invasive glaucoma surgery was performed instead of reinitiating or adding medication, according to the surgeon\u2019s standard practice. The analysis was by intention to treat. At 12 months, mean IOP reduced significantly to 14.0 \u00b1 2.9 mmHg from a baseline of 20.0 \u00b1 4.0 mmHg (\u221228%, p &lt; 0.001). Eyes with IOPs \u2264 18, \u226415, and \u226412 mmHg increased significantly vs. baseline (36.9% to 92.3%, 10.8% to 73.8%, and 3.1% to 35.4%, respectively; all p &lt; 0.001), and 89.2% of the eyes were medication-free vs. 87.7% preoperatively. Mean 12-month IOP reduction showed nonsignificant differences between eyes with or without prior SLT (\u221226% and \u221231%, respectively; p = 0.907) and among mild\/OHT, moderate, or severe glaucoma eyes (\u221228%, \u221223%, and \u221234%, respectively; p = 0.085). Postoperatively, one case each of transient corneal edema and retinal edema were observed, which self-resolved without sequelae. Thus, standalone travoprost implant administration significantly reduced IOP over 12 months in OAG and OHT, while maintaining a low medication burden. Similar IOP reductions were observed regardless of prior SLT treatment and glaucoma severity.<\/jats:p>","DOI":"10.3390\/life16040614","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:00:31Z","timestamp":1775570431000},"page":"614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension"],"prefix":"10.3390","volume":"16","author":[{"given":"Savak","family":"Teymoorian","sequence":"first","affiliation":[{"name":"Harvard Eye Associates, Laguna Hills, CA 92653, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Kaur","sequence":"additional","affiliation":[{"name":"Harvard Eye Associates, Laguna Hills, CA 92653, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-7732","authenticated-orcid":false,"given":"Dana M.","family":"Hornbeak","sequence":"additional","affiliation":[{"name":"Glaukos Corporation, Aliso Viejo, CA 92656, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Barr","sequence":"additional","affiliation":[{"name":"Glaukos Corporation, Aliso Viejo, CA 92656, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The Pathophysiology and Treatment of Glaucoma","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey","volume":"122","author":"Robin","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ophtha.2006.01.029","article-title":"24-Hour Intraocular Pressure Control with Maximum Medical Therapy Compared with Surgery in Patients with Advanced Open-Angle Glaucoma","volume":"113","author":"Konstas","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2019.02.003","article-title":"Fluctuations of the Intraocular Pressure in Medically Versus Surgically Treated Glaucoma Patients by a Contact Lens Sensor","volume":"203","author":"Muniesa","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study","volume":"127","author":"Niziol","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","article-title":"Intraocular Pressure Fluctuation","volume":"115","author":"Caprioli","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/17469899.2025.2465330","article-title":"Interventional glaucoma consensus treatment protocol","volume":"20","author":"Funke","year":"2025","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","article-title":"Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension","volume":"84","author":"Berdahl","year":"2024","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40123-025-01130-1","article-title":"Aqueous Humor Concentrations of Travoprost Free Acid and Residual Drug in Explanted Implants from Patients Administered a Travoprost Intracameral Implant","volume":"14","author":"Szekely","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s40265-024-02074-9","article-title":"Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials","volume":"84","author":"Singh","year":"2024","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OPTH.S498431","article-title":"Travoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes","volume":"19","author":"Teymoorian","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40123-024-00898-y","article-title":"Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial","volume":"13","author":"Sarkisian","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"ref_14","unstructured":"Hodapp, E., Parrish, R.K., and Anderson, D.D.R. (1993). Clinical Decisions in Glaucoma, CV Mosby Co."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","article-title":"Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)","volume":"127","author":"Medeiros","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","article-title":"Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)","volume":"81","author":"Bacharach","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/OPTH.S450220","article-title":"Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting","volume":"18","author":"Ali","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/OPTH.S445005","article-title":"Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States","volume":"18","author":"Teymoorian","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/jop.2018.0067","article-title":"Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues","volume":"35","author":"Seal","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/4\/614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:23:03Z","timestamp":1775708583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/4\/614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["life16040614"],"URL":"https:\/\/doi.org\/10.3390\/life16040614","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}